Intrinsic resistance to agents targeting phosphatidylinositol-3-kinase (PI3K)/AKT pathway is one of the major challenges in cancer treatment with such agents. The objective of this study is to identify the genes or pathways that can be targeted to overcome the resistance of non-small cell lung cancer to the AKT inhibitor, MK2206, which is currently being evaluated in phase I and II clinical trials. Using a genome-wide small interfering RNA (siRNA) library screening and biological characterization we identified that inhibition of Thioredoxin Reductase-1 (TXNRD1), one of the key anti-oxidant enzymes, with siRNAs or its inhibitor, Auranofin, sensitized non-small cell lung cancer cells to MK2206 treatment in vitro and in vivo. We found that simultaneous inhibition of TXNRD1 and AKT pathways induced robust reactive oxygen species (ROS) production, which was involved in c-Jun N-terminal Kinase (JNK, MAPK8) activation and cell apoptosis. Furthermore we found that the synthetic lethality interaction between the TXNRD1 and AKT pathways occurred through the KEAP1/NRF2 cellular antioxidant pathway. Lastly, we found that synthetic lethality induced by TXNRD1
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and AKT inhibitors relied on wild type KEAP1 function. Our study indicates that targeting the interaction between AKT and TXNRD1 antioxidant pathways with MK2206 and Auranofin, a FDA approved drug, is a rational strategy to treat lung cancer and that KEAP1 mutation status may offer a predicative biomarker for such combination approaches.
Introduction
Previous studies have established the critical role of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway in cancer cell growth and survival; therefore, strategies that target this pathway have been developed and tested for cancer treatment, including lung cancer (1) . MK2206 (Merck, Inc.), a smallmolecule inhibitor that targets the AKT signaling pathway, is currently being tested in phase I and phase II clinical trials and has demonstrated promising results in terms of tumor shrinkage, disease stabilization and patient tolerability in patients with advanced solid tumor (2) . We previously reported that a large subset of human none-small-cell-lung-cancer (NSCLC) cells do not respond to MK2206 (3).
We and others have also reported that combination with other agents, such as AZD6244 (an inhibitor of mitogen-activated protein kinase kinase) and erlotinib (an epidermal growth factor receptor [EGFR] inhibitor), sensitized some lung cancer cells to MK2206 (3, 4) . Those findings indicate that identification and inhibition of additional targets are needed to improve the efficacy of targeted therapeutic agents, such as MK2206.
Thioredoxin reductase and thioredoxin (TXNRD1/TXN) is one of the major thiol-dependent electron donor systems in cells; it plays a critical role in regulating the cellular redox environment and in a wide range of cellular activities, such as maintenance of viability and proliferation (5) . Preclinical studies indicated that Auranofin, an orally active gold compound and a TXNRD1 inhibitor, induced apoptosis in cancer cells and enhanced the antitumor activities of chemotherapeutic agents (6) (7) (8) (9) (10) . It is currently being tested in a phase II clinical trial for treatment of chronic lymphocytic leukemia (11) , and was recently repurposed as an orphan drug for human amebiasis treatment (12) . Other TXNRD1/TXN inhibitors, such as PG12, have also been tested clinically in solid tumors (13, 14) . Kelch-like ECHassociated protein (KEAP1) and nuclear factor-erythroid-derived-related factor 2 (NRF2) pathways is another major cellular antioxidant pathways. Under normal conditions, KEAP1 binds to NRF2 and promotes degradation by cullin3 (Cul3)-based E3 ligase system (15) . Activated NRF2 due to oxidative stress can stimulate multiple antioxidant molecules by binding to antioxidant response elements (AREs) (16, 17) . Loss of function mutations of KEAP1 have been reported in many cancer types including NSCLC with frequency of about 19% (18) (19) (20) . KEAP1 mutations cause constitutive activation of NRF2, which is associated with cancer progression, treatment resistance, and poor patient survival (21) (22) (23) .
Genome-wide small-interfering RNA (siRNA) library screening has been used to identify targets or networks that can be targeted for cancer therapy. siRNA library screening has also been used to identify synthetic lethality loci with specific drugs (24) (25) (26) (27) . Using genome-wide siRNA library screening and biochemical and biological methods, we found that inhibition TXNRD1 with siRNAs or inhibitor, auranofin sensitized lung cancer cells to MK2206 in vitro and in vivo. Our study indicate that Auranofin, a TXNRD1 inhibitor and clinically proven drug that has been used to treat rheumatoid arthritis for 25 years, could be repurposed for lung cancer therapy in combination with MK2206. Human lung cancer cell lines HCC193, H1993, H460, H1299, H2126, H292, H1648, H838,   H1395, H23, H358, H1703, H1666 and A549 were from the Hamon Center for Therapeutic Oncology Research at The University of Texas Southwestern Medical Center, Dallas, Texas. Cell lines were maintained in high-glucose RPMI 1640 supplemented with 5% fetal bovine serum and cultured at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. Cell lines have been authenticated regularly with STR fingerprinting method. siRNA library screening: We used the non-small-cell lung cancer cell line HCC193 for genome-wide siRNA screening, because it has a high level of p-AKT and the IC 50 for MK2206 is 10 µM (3) The screening concentration of MK2206 is 1 µM, a dose can sufficiently inhibit phosphorylated AKT (p-AKT) in vitro and in vivo (2, 3) . The screening was performed using a Dharmacon siRNA siGENOME (Dharmacon, Lafayette, CO) library containing 84,508 siRNAs with 4 unique siRNA duplexes that target each of 21,127 unique human genes. On day 1, 2000 cells were reverse transfected with 0.07 µl Dharmafect 4 in a 384-well plate, to a final concentration of 40 nM siRNA per well. MK2206 was added on day 3 at a 1µM final concentration. Cell growth was analyzed on day 5 using the CellTiter Blue method (Promega, WI). Raw data were log 2 transformed. Data were normalized using 16 negative controls in each plate. T-statistics were performed to compare the significant differences between the values of siRNA transfection and the negative control and siRNA transfection plus MK2206 treatment. P values were obtained using computed t-statistics. Beta-uniform mixture methods were used to account for multiple tests and estimate the false discovery rate (FDR).
Materials and Methods

Cell lines:
Proliferation assay: The drug treatment protocol was reported in our previous publications (3, 28) . In followed by selection with G418 (500µg/ml) for 4 weeks.
Measuring ROS production:
The ROS measurement method was described in our previous publication (30) . In brief, cells (1x10 6 /mL) were incubated in Hank's balanced saline solution containing 50 mM 2', 7'-dichlorfluorescein-diacetate (DCFHDA) for 30 minutes. The cell population fluorescence is proportional to the levels of intracellular ROS generated and was measured using fluorescenceactivated sell sorting (FACS) (Becton Dickinson, Mountain View, CA) at 588 nm emission.
Real-time polymerase chain reaction (PCR):
The NRF2 downstream molecules glutamate-cysteine ligase catalytic (GCLC) subunit was analyzed using real-time PCR as described previously (28) . The primers for GCLC forward, 5'-ctgttgcaggaaggcattgat-3' and reverse, 5'-ttcaaacagtgtcagtgggtctct-3'.
GAPDH, forward, 5′-atcccatcaccatcttccag-3′ and reverse, 5′-atgagtccttccacgatacc-3′.
Glutathione (GSH) assay: GSH levels were tested using the GSH assay kit (Sigma, St. Louis, MO).
After the indicated treatments GSH levels were determined using the GSH-reductase recycling assay with 5, 5'-Dithiobis-(2-Nitrobenzoic Acid) (DNTB) as substrate in microtiter plates, following the manufacturer's instructions. sensitivity to MK2206 and Auranofin was determined using the Fisher's exact test with two-sided P values at 95% confidence interval. Online Ingenuity software was used to perform a signaling pathway analysis. The significance of the in vitro cell proliferation between and within different treatment groups were determined using Student's t-test (two tailed). The significance of the in vivo animal study data was determined using the Kruskal-Wallis test for overall significance among different treatment groups and Mann-Whitney U test for significance between two treatment groups (two tailed). Kaplan-Meier method was used to analyze the animal survival.
Results
Synthetic lethality screening identified MK2206 synthetic lethal hits. To identify gene candidates that could be targeted to overcome the intrinsic resistance to MK2206 in NSCLC cells, genome-wide siRNA screening was performed with the Dharmacon siRNA siGENOME library in the NSCLC cell line HCC193. The false discovery rate (FDR) of 0.1 was used as the cut-off to define the significant hits.
Using a P value of 0.007542048 and at least 50% percent of growth inhibition as the cut-off, we identified 156 hits. We analyzed the significant hits using Ingenuity Pathway Analysis software and found that targets in the NF-kB, autophagy, and cellular redox regulation pathways were synthetic lethal with MK2206 ( Fig.1A and supplementary Table 1 ). Using cell proliferation assay and siRNA knockdown, we further validated the top 10 hits, including TXNRD1, CFLAR, ATP5J, SLC9A10, and CLN10. The results showed that knockdown of TXNRD1, CFLAR, SCLC9A10, AHCYL1, and CLN10 sensitized both HCC193 and H1993 cells to 1µM MK2206 (Figs. 1B and 1C ).
TXNRD1 knockdown sensitized cells to MK2206 treatment by inducing cell apoptosis.
To determine whether TXNRD1 expression levels correlate with the sensitivity to MK2206, we examined the TXNRD1 and P-AKT expression in 4 MK2206 sensitive and 10 resistant NSCLC cell lines based on our previous published data (3). We found that the expression levels of TXNRD1 are low in all 4 MK2206 sensitive cell lines, whereas the expressions of TXNRD1 are significantly higher in 7 out 10 resistant cell lines (P<0.01), and there is a correlation of TXNRD1 levels with MK2206 resistance Fig. 2A) . Knockdown of TXNRD1 with three different siRNAs significantly sensitized the HCC193 and H1993 cells (Figs. 2B and 2C ). Cell apoptosis analysis by flow cytometry confirmed that TXNRD1 knockdown combined with MK2206 induced 10%-30% apoptosis in HCC193 and H1993 cells within 48 hours treatment, whereas no apoptosis was induced in the cells treated with MK2206 or siRNA only (Fig. 2D) . PARP cleavage, an apoptosis marker was also observed in HCC193 and H1993 cells treated with TXNRD1 siRNA and MK2206 (Fig. 2E) . Those results indicate that TXNRD1 knockdown sensitizes NSCLC cells to AKT inhibition by inducing cell apoptosis.
TXNRD1 inhibition with Auranofin sensitized cells to MK2206 treatment in vitro and in vivo.
To develop a treatment strategy that would be useful clinically, we tested the combination of MK2206
and Auranofin, a TXNRD1 inhibitor that is used for rheumatoid arthritis treatment. Inhibition of TXNRD1 by different doses of Auranofin was firstly confirmed in HCC193 cells. Approximately 80% percent of TXNRD1 activity was inhibited by 0.1 µM Auranofin (Fig. 3A) , which is consistent with a previous report Fig. 3F ). This combination also 
significantly prolonged animal survival (median 76 days) compared with vehicle (median 31 days) or single drug treatment (median 34 days for both single treatments), P<0.001) (Fig. 3G ). Significant Inhibition of TXNRD1 by Auranofin and Auranofin and MK2206 combination treatment was confirmed in animal tumor tissues (Fig. 3H) . Immunohistochemical staining indicated that p-AKT was inhibited in the tumor tissue treated with MK2206 or the combination (Fig. 3I) . These results indicate that the combination of MK2206 and Auranofin induces synthetic lethality in vivo.
Combination of Auranofin and MK2206 induced ROS production, which mediated cell apoptosis.
Because TXNRD1/TNX is one of the major cellular redox regulatory systems that regulate cellular reactive oxygen species (ROS), we hypothesized that combination of Auranofin and MK2206 may disrupt the cellular ROS balance. Indeed, we found that MK2206 alone induced ROS production in HCC193 and H1993 cells by approximately 2 folds (Fig. 4A) . The combination of Auranofin and MK2206 induced robust ROS production by 5 folds (P<0.05) (Fig. 4B) . To determine whether ROS induction is essential for cell apoptosis induced by MK2206 and Auranofin, we treated cells with the ROS blocker nordihydroguaiaretic acid (NDGA) (20 µM). NDGA blocked the ROS production in HCC193 and H1993 cells induced by the combination (Fig. 4C) , and reversed cell growth inhibition in both HCC193 and H1993 cells (Fig. 4D) . High level of ROS can activate JNK pathway which mediated cell apoptosis (34) . Indeed, we observed that combination of MK2206 and Auranofin induced activation and PARP cleavage in H1993 and HCC193 cells (Fig. 4E ). In addition, JNK activation and PARP cleavage were blocked by ROS inhibitor NDGA (Fig. 4F) . Those results indicated that combination of MK2206 and Auranofin induced ROS production, which mediated the cell apoptosis.
Synthetic lethality induced by Auranofin and MK2206 is through the KEAP1/NRF2 pathway.
In addition to TXNRD1, KEAP1/NRF2 is another major cellular antioxidant system. Activated NRF2 translocates to the nucleus and stimulates gene expression, such as glutamate--cysteine ligase catalytic subunit (GCLC) and NAD(P)H dehydrogenase, quinone1 (NQO1) which mediate cellular antioxidant responses (35) (36) (37) . To determine whether AKT inhibition induced ROS production was due to NRF2 inhibition, subcellular localization of NRF2 was examined using immunofluorescence staining. The results showed NRF2 was excluded from the nuclei in the H1993 cells treated with 1 µM MK2206 (Fig. 5A) . Luciferase reporter assay confirmed that MK22006 inhibited GCLC promoter activity in HCC193 and H1993 cells (Fig. 5B) indicating that the transcriptional activity of NRF2 was inhibited by MK2206. Similarly, a dominant negative form of AKT (AKT-DN) inhibited the transcriptional activity of NRF2 in HCC193 and H1993 cells in a luciferase reporter assay (Figs. 5C and 5D) , and reduced NRF2 in the nuclear fractions of H1993 cells (Fig. 5E ). Down-regulation of GCLC mRNA was also observed in both HCC193 and H1993 cells with a time point dependent manner (Fig. 5F ). Because GCLC is a ratelimiting molecule for GSH synthesis and GSH is the major ROS scavenger, we further determined GSH production in cells treated with MK2206. The GSH level was dramatically reduced in cells treated with MK2206 or combination in HCC193 and H1993 cells (Fig. 5G) . These results indicate that MK2206 inhibited NRF2 transcriptional activity and its downstream molecules, such as GCLC, which subsequently reduced the GSH level and resulted in ROS induction.
Synthetic lethality induced by MK2206 and Auranofin depends on the genetic status of KEAP1.
The above results indicate that the synthetic lethality induced by MK2206 and Auranofin is mediated by ROS through concurrent inhibition of NRF2 and TXNRD1, two major cellular redox regulators. Because KEAP1 mutations cause constitutive activation of NRF2 (38, 39), which we expect will not be inhibited by MK2206 and thereby cause resistance to MK2206 and Auranofin combination. To test this hypothesis, we tested 5 additional KEAP1 wild type cell lines (H1299, H23, H358, H292, and H1703), 5 KEAP1 inactive mutant cell lines (H460, A549, H2126, H1648, and H838), and 2 heterozygous mutant cell lines (H1993 and H1395) for their sensitivity to treatment with MK2206, Auranofin, or both (18, 19) .
All KEAP1 wild-type cell lines and heterozygous mutant cell lines were sensitive to MK2206-Auranofin combination based on the IC50s of MK2206 which are bellow or close to 1 µM, a clinical achievable dose ( Fig. 6A and supplementary Table 1 ). In contrast, all KEAP1 mutant cells were not responsive to the combination treatment (IC50s of MK2206 are more than the 3 µM) (Fig. 6B and (Fig. 6C) . Our results indicate that synthetic lethality induced by MK2206 and Auranofin depends on the genetic status of KEAP1. Using an EGFP-NRF2 fusion protein, we confirmed that MK2206 induced NRF2 nuclear exclusion in KEAP1 wild-type H1299 cells but not in KEAP1 mutant H460 cells (Fig. 6D) . Moreover, MK2206 could not inhibit NRF2 transcriptional activity by MK2206 in KEAP1 mutant H460 and A549 cells in a Luciferase reporter assay (Fig. 6E) . These results indicate that constitutive activation of NRF2 due to inactive KEAP1 mutations cannot be overcome by MK2206 thus causing resistance to the Auranofin and MK2206 combination. To further confirm this, KEAP1was stably knocked down in KEAP1 wild-type H1299 cells (Fig. 6F, left) . KEAP1 knockdown rendered cells resistance to the combination treatment ( Figure 6H .
DISCUSSION
In this study we performed a genome-wide siRNA library screen with NSCLC cell line HCC193 to identify the genes that can be targeted to sensitize the cells to AKT inhibitor MK2206. This screening revealed 156 MK2206 synthetic lethality hits (genes) with a false discover rate (FDR) of 0.1, and a minimum 50% inhibition with combination of siRNA and 1 µM MK2206. Those hits include previously reported autophagy-related genes, such as MAP1LC3C, cathepsin E, and cathepsin H, and CAN-13-0712 components in the NF-B pathway, such as CASP8 and CFLAR. Inhibition of autophagy could sensitize the cells to PI3K/AKT inhibitor treatment, which has been reported previously (40, 41). Other hits include ATPases and ATP synthase members, such as ATP5J and ATP6V1B1, both of which are H+ transporters. The synthetic lethality interaction between AKT and ATPases may occur through the autophagy pathway since previous studies reported that the vacuolar membrane H+-ATPase plays an important role in autophagy (42, 43) . The synthetic lethality hits are related to different pathways, and many of those hits or pathways have crosstalk (44, 45) . This screening result confirmed some previous finding such as synthetic lethality induced by autophagy and AKT inhibition but also revealed some novel targets, such as TXNRD1, the molecules in redox balance, suggesting potential synthetic lethal interactions between the redox regulation system and AKT pathways.
Previous studies indicate that other pathways, such as KEAP1/NRF2, may compensate some functions of the TXNRD1/TXN in cancer cells especially in vivo. In addition, oncogenic pathways such as KRAS and NF-KB also regulate the cellular redox balance through interaction with TXNRD1 or KEAP1/NRF2 (46-49), suggesting complicated interaction between oncogenic signaling pathways and cellular redox balance system. Here we showed that concurrently inhibited TXNRD1 and AKT pathways with Auranofin and MK2206 respectively induced robust ROS production and NSCLC cell apoptosis in vitro and tumor growth inhibition in vivo, which was not achieved by each drug alone. More importantly, NDGA, a ROS blocker, rescued the cell growth inhibition, JNK activation and PARP cleavage induced by the Auranofin and MK2206 combination. Our results indicate that interruption of the cellular redox balance plays an important role in the synthetic lethality induced by simultaneous inhibition of TXNRD1 and AKT. We found that MK2206 inhibited the NRF2 activity and reduced the GSH level through downregulating GCLC expression, which is consistent with a recent study that inhibition of mammalian target of rapamycin (mTOR) reduced GSH level and induced ROS in KRAS mutant lung cancer (50). Since mTOR pathway is regulated by AKT, it is also possible that MK2206 induced ROS production may be In summary, we identified a set of synthetic loci that could be targeted to improve the antitumor activity of AKT inhibitor MK2206. We discovered that the synthetic lethal interaction between the AKT pathway and TXNRD1 occurs through the KEAP1/NRF2 antioxidant system, and targeting such interaction with a combination of AKT inhibitor and Auranofin is a promising approach for lung cancer therapy, with KEAP1 mutation status as a genetic biomarker of drug sensitivity.
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